Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMUS-CABG
2025-521892-30-00Phase 3Authorised
- Sponsor
- Medinet Heart Centre
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of aspirin and prasugrel in coronary arteriosclerosis and Chronic Coronary Syndrome (CCS) (3 arms), sponsored by Medinet Heart Centre. Primary endpoint: Proportion of failed grafts at 12 months (prasugrel + aspirin vs high-dose aspirin vs low-dose aspirin). Planned start Sep 2025; status: authorised.
02
Drugs
aspirinprasugrel
03
Conditions
coronary arteriosclerosisChronic Coronary Syndrome (CCS)
Beyond the preview
Go deeper on 2025-521892-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521892-30-00.